Form 8-K - Current report:
SEC Accession No. 0001558370-25-000823
Filing Date
2025-02-12
Accepted
2025-02-12 07:36:10
Documents
15
Period of Report
2025-02-10
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K xlo-20250210x8k.htm   iXBRL 8-K 67942
2 EX-99.1 xlo-20250210xex99d1.htm EX-99.1 23991
3 EX-99.2 xlo-20250210xex99d2.htm EX-99.2 26920
  Complete submission text file 0001558370-25-000823.txt   263171

Data Files

Seq Description Document Type Size
4 EX-101.SCH xlo-20250210.xsd EX-101.SCH 3402
5 EX-101.LAB xlo-20250210_lab.xml EX-101.LAB 16578
6 EX-101.PRE xlo-20250210_pre.xml EX-101.PRE 10708
17 EXTRACTED XBRL INSTANCE DOCUMENT xlo-20250210x8k_htm.xml XML 5045
Mailing Address 828 WINTER STREET WALTHAM MA 02451
Business Address 828 WINTER STREET WALTHAM MA 02451 617-833-1027
Xilio Therapeutics, Inc. (Filer) CIK: 0001840233 (see all company filings)

EIN.: 851623397 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40925 | Film No.: 25611977
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)